BACKGROUND: Acute phase of human immunodeficiency virus (HIV) infection (AHI) may account for a significant proportion of HIV-1 transmission. We identified and characterized individuals in Nigeria with AHI. METHODS: Individuals were tested using a combination of rapid HIV testing in mobile units and laboratory-based specimen pooling for nucleic acid amplification testing. Genome sequences were characterized. A linear segmented regression model was fit to serial viral load (VL) measurements to characterize early VL profiles. RESULTS: Sixteen AHIs were identified from 28 655 persons screened. Specimens were genotyped: 7 (43.8%) were CRF02_AG, 6 (37.5%) were subtype G, 1 (6.3%) was CRF06_cpx, and 2 (12.5%) were unique recombinant forms. No antiretroviral resistance mutations were detected. The mean duration of high VL burden from peak to nadir was 76 days (95% confidence interval [CI], 58-93 days), and the mean rate of viremic control was -0.66 log(10) VL per month. The mean VL at set-point was 4.5 log(10) copies/mL (95% CI, 3.9-5.1 log(10) copies/mL). CONCLUSIONS: This study is the first to characterize AHI among Nigerians identified as HIV infected before seroconversion who would be otherwise missed by conventional HIV testing. Infections by HIV subtypes in Nigeria exhibit long periods of high viral burden, which can contribute to increased transmissibility.
BACKGROUND: Acute phase of human immunodeficiency virus (HIV) infection (AHI) may account for a significant proportion of HIV-1 transmission. We identified and characterized individuals in Nigeria with AHI. METHODS: Individuals were tested using a combination of rapid HIV testing in mobile units and laboratory-based specimen pooling for nucleic acid amplification testing. Genome sequences were characterized. A linear segmented regression model was fit to serial viral load (VL) measurements to characterize early VL profiles. RESULTS: Sixteen AHIs were identified from 28 655 persons screened. Specimens were genotyped: 7 (43.8%) were CRF02_AG, 6 (37.5%) were subtype G, 1 (6.3%) was CRF06_cpx, and 2 (12.5%) were unique recombinant forms. No antiretroviral resistance mutations were detected. The mean duration of high VL burden from peak to nadir was 76 days (95% confidence interval [CI], 58-93 days), and the mean rate of viremic control was -0.66 log(10) VL per month. The mean VL at set-point was 4.5 log(10) copies/mL (95% CI, 3.9-5.1 log(10) copies/mL). CONCLUSIONS: This study is the first to characterize AHI among Nigerians identified as HIV infected before seroconversion who would be otherwise missed by conventional HIV testing. Infections by HIV subtypes in Nigeria exhibit long periods of high viral burden, which can contribute to increased transmissibility.
Authors: F R Cleghorn; N Jack; J K Carr; J Edwards; B Mahabir; A Sill; C B McDanal; S M Connolly; D Goodman; R Q Bennetts; T R O'Brien; K J Weinhold; C Bartholomew; W A Blattner; M L Greenberg Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205
Authors: Simon M Agwale; Clement Zeh; Ellen Paxinos; Lilian Odama; Danuta Pienazek; Charles Wambebe; Marcia L Kalish; Rainer Ziermann Journal: AIDS Res Hum Retroviruses Date: 2006-01 Impact factor: 2.205
Authors: D J Hu; S Vanichseni; T D Mastro; S Raktham; N L Young; P A Mock; S Subbarao; B S Parekh; L Srisuwanvilai ; R Sutthent; C Wasi; W Heneine; K Choopanya Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: T C Quinn; R Brookmeyer; R Kline; M Shepherd; R Paranjape; S Mehendale; D A Gadkari; R Bollinger Journal: AIDS Date: 2000-12-01 Impact factor: 4.177
Authors: Clive M Gray; Carolyn Williamson; Helba Bredell; Adrian Puren; Xiaohua Xia; Ruben Filter; Lynn Zijenah; Huyen Cao; Lynn Morris; Efthyia Vardas; Mark Colvin; Glenda Gray; James McIntyre; Rosemary Musonda; Susan Allen; David Katzenstein; Mike Mbizo; Newton Kumwenda; Taha Taha; Salim Abdool Karim; Jorge Flores; Haynes W Sheppard Journal: AIDS Res Hum Retroviruses Date: 2005-04 Impact factor: 2.205
Authors: Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex Journal: PLoS One Date: 2010-04-12 Impact factor: 3.240
Authors: Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn Journal: PLoS Pathog Date: 2009-09-18 Impact factor: 6.823
Authors: Jibreel Jumare; Nicaise Ndembi; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Patrick Dakum; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; William A Blattner; Walter Royal Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: A A Adetunji; M A Kuti; R A Audu; S A Muyibi; M Imhansoloeva; O A Mosuro; E A Solanke; O M Akpa; A E Irabor; Mma Ladipo; B Berzins; K Robertson; A Ogunniyi; I F Adewole; B O Taiwo Journal: HIV Med Date: 2017-07-31 Impact factor: 3.180
Authors: Erik Billings; Gustavo H Kijak; Eric Sanders-Buell; Nicaise Ndembi; Anne Marie OʼSullivan; Sylvia Adebajo; Afoke Kokogho; Mark Milazzo; Kara Lombardi; Stefan Baral; Rebecca Nowak; Habib Ramadhani; Robert Gramzinski; Merlin L Robb; Nelson L Michael; Manhattan E Charurat; Julie Ake; Trevor A Crowell; Sodsai Tovanabutra Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Mohammad M Sajadi; Maham Farshidpour; Eric P Brown; Xin Ouyang; Michael S Seaman; Marzena Pazgier; Margaret E Ackerman; Harriet Robinson; Georgia Tomaras; Matthew S Parsons; Manhattan Charurat; Anthony L DeVico; Robert R Redfield; George K Lewis Journal: J Infect Dis Date: 2015-09-07 Impact factor: 5.226
Authors: Paul E Oluniyi; Fehintola V Ajogbasile; Shuntai Zhou; Iyanuoluwa Fred-Akintunwa; Christina S Polyak; Julie A Ake; Sodsai Tovanabutra; Michael Iroezindu; Morgane Rolland; Christian T Happi Journal: AIDS Date: 2022-01-01 Impact factor: 4.632
Authors: Richard A Heipertz; Ojor Ayemoba; Eric Sanders-Buell; Kultida Poltavee; Phuc Pham; Gustavo H Kijak; Esther Lei; Meera Bose; Shana Howell; Anne Marie OʼSullivan; Adam Bates; Taylor Cervenka; Janelle Kuroiwa; Akindiran Akintunde; Onyekachukwu Ibezim; Abraham Alabi; Obumneke Okoye; Mark Manak; Jennifer Malia; Sheila Peel; Mohammed Maisaka; Darrell Singer; Robert J O'Connell; Merlin L Robb; Jerome H Kim; Nelson L Michael; Ogbonnaya Njoku; Sodsai Tovanabutra Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889
Authors: Ogbonnaya S Njoku; Mark M Manak; Robert J O'Connell; Ashley L W Shutt; Jennifer A Malia; Richard A Heipertz; Sodsai Tovanabutra; Mark J Milazzo; Gideon Akindiran Akintunde; Abraham S Alabi; Aminu Suleiman; Amos A Ogundeji; Terfa S Kene; Robbie Nelson; Ojor R Ayemoba; Darrell E Singer; Merlin L Robb; Sheila A Peel; Nelson L Michael Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240